Drugs / Cergutuzumab Amunaleukin
Cergutuzumab Amunaleukin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02350673 | Jun 2015 → Dec 2019 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02004106 | Dec 2013 → Aug 2016 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cergutuzumab Amunaleukin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02350673 ↗ |
| Known as | Cergutuzumab amunaleukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990018 ↗ |
| Known as | Cergutuzumab amunaleukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990018 ↗ |
| Known as | RG-7813 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990018 ↗ |
| Known as | RO6895882 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02004106 ↗ |
| Modality | Protein / enzyme biologic | “Cergutuzumab Amunaleukin, an Immunocytokine, Which Consists of a Variant of Interleukin 2 (IL 2v)” NCT02350673 ↗ |
| Route | Intravenous | “Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.” NCT02004106 ↗ |